Workflow
宏力医疗管理(09906) - 2022 - 年度业绩
HONLIV HEALTHHONLIV HEALTH(HK:09906)2023-03-27 14:56

Revenue and Financial Performance - The total revenue for the year ended December 31, 2022, increased by 19.9% to RMB 727.8 million from RMB 606.8 million for the year ended December 31, 2021, primarily due to an increase in outpatient and inpatient patient visits and average patient fees[13]. - Revenue for the year ended December 31, 2022, was RMB 727,789,000, representing a 19.9% increase from RMB 606,837,000 in 2021[130]. - Gross profit for the same period was RMB 138,395,000, a slight increase of 2.3% compared to RMB 135,306,000 in 2021[130]. - Profit attributable to equity holders of the company was RMB 48,947,000, reflecting a significant growth of 33.7% from RMB 36,615,000 in the previous year[130]. - Basic and diluted earnings per share increased to RMB 0.08, up 33.3% from RMB 0.06 in 2021[130]. - Operating profit for the year was RMB 61,561,000, down from RMB 66,561,000 in 2021[131]. - The net profit before tax for the year was RMB 63,021,000, an increase of 24.7% from RMB 50,542,000 in 2021[156]. - Revenue from medical services was RMB 463,225,000, up 17.9% from RMB 392,356,000 in the previous year[143]. - Revenue from pharmaceutical sales reached RMB 264,564,000, representing a 23.4% increase from RMB 214,481,000 in 2021[143]. Patient Visits and Service Metrics - Outpatient visits increased to 1,286,815 in 2022 from 1,183,408 in 2021, with the average outpatient fee rising to RMB 312.7 from RMB 265.7[13]. - Inpatient visits rose to 50,920 in 2022 compared to 43,973 in 2021, while the average inpatient fee decreased slightly to RMB 6,385.2 from RMB 6,645.4[13]. - The total number of inpatient visits increased by 15.8% to 50,920 for the year ended December 31, 2022, compared to 43,973 for the year ended December 31, 2021[181]. - The average cost per inpatient visit decreased by 3.9% to RMB 6,385.2 for the year ended December 31, 2022, from RMB 6,645.4 for the year ended December 31, 2021[181]. - The average cost per outpatient visit increased by 17.7% to RMB 312.7 for the year ended December 31, 2022, compared to RMB 265.7 for the year ended December 31, 2021[181]. Expenses and Liabilities - Administrative expenses increased by 7.0% to RMB 73.3 million in 2022 from RMB 68.5 million in 2021, mainly due to higher employee welfare expenses and taxes from a new building[22]. - The cost of consumables for the year ended December 31, 2022, increased by RMB 17.3 million compared to the previous year[31]. - Employee benefits expenses rose by RMB 17.9 million for the year ended December 31, 2022, compared to the previous year[31]. - Depreciation and amortization expenses increased by RMB 21.0 million for the year ended December 31, 2022, compared to the previous year[31]. - The company has rental liabilities of approximately RMB 2.1 million as of December 31, 2022[37]. - Total liabilities decreased to RMB 380,367,000 from RMB 395,079,000 in the previous year[121]. - Non-current liabilities increased to RMB 2,911,000 from RMB 2,534,000 in 2021[121]. - Current liabilities totaled RMB 377,456,000, a decrease from RMB 392,545,000 in the previous year[121]. Cash Flow and Financing Activities - Operating cash flow increased from RMB 914 million for the year ended December 31, 2021, to RMB 1,185 million for the year ended December 31, 2022, primarily due to increased operating profit[53]. - Net cash used in investing activities decreased from RMB 505 million for the year ended December 31, 2021, to RMB 192 million for the year ended December 31, 2022, mainly due to a reduction in payments for the purchase of properties, plants, and equipment by RMB 321 million[54]. - Net cash used in financing activities increased from RMB 769 million for the year ended December 31, 2021, to RMB 1,178 million for the year ended December 31, 2022, primarily due to repayment of borrowings and related interest of RMB 565 million[54]. - The company's debt-to-asset ratio as of December 31, 2022, was 40.7%, a slight decrease from 41.1% as of December 31, 2021[56]. Strategic Initiatives and Future Plans - The company plans to continue expanding its business scale through external growth and management strategies[18]. - The company aims to enhance talent cultivation and strengthen partnerships with educational institutions to build a professional medical team[17]. - The company plans to expand its services through an online hospital platform, enabling online consultations and electronic prescriptions[51]. - The company is developing new medical technologies, including ultrasound-guided procedures, to enhance its competitive edge[52]. - The company aims to establish a multidisciplinary treatment model to address various patient needs, including lung nodules and pain management[51]. - The company plans to enhance core competitiveness and expand service capabilities in response to increasing healthcare demands[185]. - The government has introduced policies to support the development of social medical institutions, indicating a favorable environment for future growth[186]. Research and Community Engagement - The company published 55 medical research papers in 2022, including 5 at the national level and 32 at the provincial level[35]. - The company is committed to social welfare activities to enhance community healthcare[29]. - The company is actively involved in social welfare activities, completing over 2,000 free screenings for lung nodules during the reporting period[49]. - The company believes that social healthcare will continue to grow with the support of national policies, aiming to meet the increasing healthcare demands of the public[6]. Corporate Governance and Compliance - As of December 31, 2022, the company has complied with all applicable corporate governance code provisions except for the specified provisions[87]. - The audit committee, consisting of three independent non-executive directors, has reviewed the consolidated financial statements for the year ended December 31, 2022[91]. - The company's auditor confirmed that the financial figures in the announcement are consistent with the audited financial statements[92]. - The annual general meeting is scheduled for June 16, 2023, where shareholders will be invited to participate[96]. - The company expresses gratitude to its management team and employees for their contributions to its success[98].